Boehringer Ingelheim Vetmedica, Inc. Expands Sales Force; Adds 75 New Positions
Published: Sep 27, 2012
The increased sales force will help BIVI continue to support its expanding product lines as well as meet the needs of customers across all market segments.
"Our decision to increase the number of sales representatives in the field was made for the benefit of our customers," says Tim Bettington, vice president sales and marketing, BIVI. "We are continuing to grow as a company and we wouldn't be able to do that if it weren't for the loyalty of our customers. The additional representatives will allow us to work directly with more customers, creating more opportunity to meet their needs."
Since BIVI's acquisition of certain Fort Dodge Animal Health assets in 2009, the company has nearly doubled in size, both in terms of product offerings and number of employees. Dr. Albrecht Kissel, president and CEO, adds that it is BIVI's drive for innovation that continues to fuel the business growth.
"We are dedicated to our customers and the animal health industry," says Kissel. "Not only do we want to ensure we are developing technological innovations with our products, but also that we are providing the best customer service."
Bettington adds that expansion of the sales force is indicative of the value BIVI sees in customer relationships.
"By increasing the number of representatives we have in the field, we are increasing our ability to engage customers, provide innovative solutions and assist in the pursuit of delivering the best medicine," says Bettington.
BIVI plans to post positions during the fourth quarter of 2012. For more information about Boehringer Ingelheim Vetmedica, Inc. careers visit www.bi-vetmedica.com/careers.html
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic factors in all of Boehringer Ingelheim's endeavours.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5 percent of its net sales.
SOURCE Boehringer Ingelheim Vetmedica, Inc.